Breakthrough in lung cancer treatment
Added: Monday 1 June 2015
Research presented at ASCO shows that a new lung cancer therapy can double life expectancy in some patients. Nivolumab stops cancer cells from switching off the immune system, allowing the body to continue fighting the tumour. Cancer cells can produce a protein called PD-L1 which blocks attacks from the immune system, but Nivolumab stops them doing this. This has led to an overall increase in life expectancy, with spectacular results in some patients. The Spanish researchers described their work as a milestone.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: